IP Library Granted Patent US 8,236,562
Granted Patent B2
US 8,236,562 · App. 10/362,715 · Granted Aug 7, 2012

Method for producing ready to use, antigen-loaded or unloaded, cryoconserved mature dendritic cells

Assignee: Argos Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,236,562
App. No.
10/362,715
Granted
Aug 7, 2012
Kind
B2
Abstract

The invention relates to a method for producing ready to use, antigen loaded or unloaded, cryoconserved mature dendritic cells especially for the production of a vaccine containing said dendritic cells, wherein immature dendritic cells are cultivated in the presence of suitable maturation stimuli and the mature dendritic cells thus obtained are frozen. The dendritic cells can be loaded with antigen before freezing. The invention also relates to a vaccine which can be obtained according to the inventive method and to a composition containing frozen, mature dendritic cells which are loaded with antigen.

Claims (24)

1. A method for preparation of ready-to-use cryoconserved mature dendritic cells, the method comprising:

(a) providing immature dendritic cells:

(b) culturing the immature dendritic cells in a culture medium containing a maturing cocktail comprising maturing stimulants IL-1β, IL-6, PGE 2 , and TNF-α to obtain mature dendritic cells, wherein said culture medium contains from 0.1 to 100 ng/ml IL-1β, from 0.1 to 100 ng/ml IL-6, from 0.1 to 1.0 μg/ml prostaglandin E 2 (PGE 2 ), and from 0.1 to 100 ng/ml TNF-α; and

(c) freezing the mature dendritic cells at a concentration of from 5×10 6 cells/ml to 20×10 6 cells/ml in a freezing medium comprising:

(i) autologous serum or autologous plasma;

(ii) 5-25% DMSO; and

(iii) 5-10% glucose,

to obtain frozen dendritic cells suitable after thawing for administration to a patient.

2. A method for preparation of ready-to-use cryoconserved mature dendritic cells, the method comprising:

(a) providing immature dendritic

(b) culturing the immature dendritic cells in a culture medium containing a maturing cocktail comprising IL-1, IL-6, prostaglandin E 2 (PGE 2 ) and TNFα to obtain mature dendritic cells: and

(c) freezing the mature dendritic cells at a concentration of from 5×10 6 cells/ml to 20×10 6 cells/ml in a freezing medium comprising:

(i) autologous serum or autologous plasma;

(ii) 5-25% DMSO; and

(iii) 5-10% glucose,

to obtain frozen dendritic cells suitable after thawing for administration to a patient.

3. A method for preparation of ready-to-use cryoconserved mature dendritic cells, the method comprising:

(a) providing immature dendritic cells:

(b) culturing the immature dendritic cells in a culture medium containing a maturing cocktail comprising interleukin 1β (IL-1β), interleukin 6 (IL-6), prostaglandin E 2 (PGE 2 ), and tumor necrosis factor α (TNFα) to obtain mature dendritic cells; and

(c) freezing the mature dendritic cells at a concentration of from 5×10 6 cells/ml to 20×10 6 cells/ml in a freezing medium comprising:

(i) autologous serum or autologous plasma;

(ii) 5-25% DMSO; and

(iii) 5-10% glucose,

to obtain frozen dendritic cells suitable after thawing for administration to a patient, wherein said dendritic cells are loaded with an antigen prior to said freezing, and wherein said antigen is a protein or a fragment thereof having at least 8 amino acids- and is added to the culture medium in a concentration of from 0.01 to 1000 μM.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2019
From: ARGOS THERAPEUTICS, INC.
To: COIMMUNE, INC.
Reel/Frame 048645/0673 →
CHANGE OF NAME Recorded May 24, 2007
From: MERIX BIOSCIENCE, INC.
To: ARGOS THERAPEUTICS, INC.
Reel/Frame 019340/0373 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2003
From: SCHULER, GEROLD; SCHULER-THURNER, BEATRICE
To: MERIX BIOSCIENCE, INC.
Reel/Frame 014168/0197 →
Priority Claims (1)
DE 100 41 515 · Aug 24, 2000 · national
Continuity (1)
Related Publication 20040253574A1 · Dec 16, 2004